CVS Health comments on Gilead hepatitis drug deal

WOONSOCKET, R.I. — CVS Health has confirmed that after a thorough evaluation of the existing and new hepatitis C therapies that are now available in the marketplace, Gilead Sciences’ Harvoni and Sovaldi drugs will be exclusive to CVS Health’s Standard Commercial, Exchange (Marketplace), Medicare Part D and Medicaid formularies, effective Jan. 7.

“Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C. When making this decision, we evaluated a wide variety of factors including duration of therapy, relative distribution of genotype and cost of the individual agents in the category as well as the results of a comprehensive clinical review of the different hepatitis C regimens,” said CVS Health spokesperson Christine K. Cramer in a statement sent to Drug Store News. “We believe this strategy meets patient needs while delivering excellent value and clinical options to both clients and plan members.”

As noted in a New York Times article, the move partially offsets Express Scripts’ announcement in late December that AbbVie Viekira Pak will be the exclusive option for Genotype 1 hepatitis C patients covered by the Express Scripts National Preferred Formulary, and that, beginning Jan. 1, Sovaldi, Harvoni and Olysio (simeprevir) will be excluded from the National Preferred Formulary.

 

Login or Register to post a comment.